Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Guggenheim

Benzinga's Top Ratings Upgrades, Downgrades For November 7, 2022

Benzinga's Top Ratings Upgrades, Downgrades For October 31, 2022

Benzinga's Top Ratings Upgrades, Downgrades For October 31, 2022

Meta Platforms To $200? These Analysts Slash Price Targets On Meta Following Q3 Results

Meta Platforms To $200? These Analysts Slash Price Targets On Meta Following Q3 Results

Meta Platforms, Inc. (NASDAQ: META) reported worse-than-expected Q3 EPS and issued Q4 revenue guidance with a midpoint below estimates. The company also guided FY23 expenses of $96 billion to $101 billion. Meta Platforms shares dropped 22.1% to $101.20 on Thursday.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Benzinga's Top Ratings Upgrades, Downgrades For October 24, 2022

Etsy Whale Trades Spotted

A whale with a lot of money to spend has taken a noticeably bearish stance on Etsy. Looking at options history for Etsy (NASDAQ:ETSY) we detected 27 strange trades.

Benzinga's Top Ratings Upgrades, Downgrades For October 13, 2022

Benzinga's Top Ratings Upgrades, Downgrades For October 10, 2022

inkl

Read news from The Economist, FT, and more,
with one subscription

Women artists: the belated craze for blockbuster shows is welcome – but it's not enough

Women artists: the belated craze for blockbuster shows is welcome – but it's not enough

The Barbican’s boldly curated exhibiton of abstract expressionist Lee Krasner (1908-1984) – who was routinely referred to as Jackson Pollock’s wife, despite being a well-established artist long before meeting him – transferred to the Guggenheim Bilbao in 2018. Before it opened, a Spanish newspaper invited me to introduce this “little…

The Conversation

Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2022

Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2022

Laura Poitras film spotlights activist photographer Goldin

Laura Poitras film spotlights activist photographer Goldin

Laura Poitras' Nan Goldin documentary "All the Beauty and the Bloodshed,” is having its world premiere at the Venice Film Festival on Saturday, where it is part of the main competition slate

The Independent UK

Benzinga's Top Ratings Upgrades, Downgrades For September 2, 2022

Benzinga's Top Ratings Upgrades, Downgrades For September 2, 2022

5 Kohl's Analysts On Bloated Inventory, Guidance Cut: 'Fundamentals Are Likely To Get Worse'

5 Kohl's Analysts On Bloated Inventory, Guidance Cut: 'Fundamentals Are Likely To Get Worse'

Kohl's Corporation (NYSE: KSS) shares are down 4% on Friday after the company cut its guidance and said inflation is eating into its sales growth.

Minneapolis-published Ada Limón is named US Poet Laureate

The Guggenheim fellow has published four books of poetry with Minneapolis' Milkweed Editions.

Tribune News Service

Read How Analysts Reacted To Kohl's Conclusion Of Strategic Review Process

Read How Analysts Reacted To Kohl's Conclusion Of Strategic Review Process

Telsey Advisory Group analyst Dana Telsey has lowered the price target on Kohl's Corp (NYSE:KSS) to $35 (19% upside) from $55 and kept the Market Perform rating on the shares. Kohl's abandoned its negotiations with Franchise Group, considering the challenges in the current retail and financing environment. Also, the retail chain has cut its Q2 sales guidance on ongoing inflationary…

Get all your
news in one place.

100's of premium titles.
One news app.

New Chelsea owner Todd Boehly - how rich is he and how did he make his money?

Todd Boehly is to be the new face of Chelsea Football Club, as his consortium secures permission to complete the sale of the west London outfit from Roman Abramovic after he bought it in 2003

The Guardian - UK

Todd Boehly’s vision for Chelsea? Glossy spectacle and ruthless profit

Judging by his time with the Los Angeles Dodgers, Boehly will sanction big spending as long as he sees even bigger returns

SVB Sees De-Risked Opportunity For This Newly Listed Norovirus Vaccine

SVB Leerink is initiating coverage of HilleVax Inc (NASDAQ:HLVX) shares with an Outperform rating and a $30 price target. The analyst believes the company’s potentially first-in-class infant norovirus vaccine HIL214 represents a uniquely de-risked opportunity. It estimates $625 million in risk-adjusted infant HIL214 sales in 2030E ($1 billion unadjusted). The outlook is supported by…

Guggenheim Maintains Buy Rating for Meta Platforms: Here's What You Need To Know

Guggenheim has decided to maintain its Buy rating of Meta Platforms (NASDAQ:FB) and lower its price target from $275.00 to $250.00. Shares of Meta Platforms are trading down 2.94% over the last 24 hours, at $196.67 per share.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga's Top Ratings Upgrades, Downgrades For May 5, 2022

What To Know About Guggenheim's Downgrade of Spotify Technology

Guggenheim downgraded its rating of Spotify Technology (NYSE:SPOT) to Neutral with a price target of $95.00, changing its price target from $200.00 to $95.00. Shares of Spotify Technology are trading down 12.12% over the last 24 hours, at $97.03 per share.

Benzinga's Top Ratings Upgrades, Downgrades For April 14, 2022

Guggenheim Maintains Buy Rating for Albertsons Companies, Raises Price Target To $37

Guggenheim has decided to maintain its Buy rating of Albertsons Companies (NYSE:ACI) and raise its price target from $34.00 to $37.00. Shares of Albertsons Companies are trading up 4.41% over the last 24 hours, at $33.38 per share.

Guggenheim Maintains Buy Rating for Rubius Therapeutics, Lowers Price Target To $5

Guggenheim has decided to maintain its Buy rating of Rubius Therapeutics (NASDAQ:RUBY) and lower its price target from $25.00 to $5.00. Shares of Rubius Therapeutics are trading down 24.14% over the last 24 hours, at $2.42 per share.

Why This Teladoc Health Analyst Expects 25%-30% Revenue Growth

Teladoc Health Inc (NYSE: TDOC) is a market leader in digital services, and the breadth of its services is unmatched, according to Guggenheim. The Teladoc Health Analyst: Sandy Draper initiated coverage of Teladoc Health with a Buy rating and $96 price target.

Benzinga's Top Ratings Upgrades, Downgrades For April 7, 2022

1 2 3 4 5

People

Roman Abramovich

Jackson Pollock

Artemisia Gentileschi

Lorraine Hutchinson

Camille Claudel

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Bank of America

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

407,401 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play